Mavorixafor: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Mavorixafor. Educational only — not medical advice.
Labeled uses
XOLREMDI is indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lympocytes.
Source: FDA labeling via NIH DailyMed (set 7f3a5ee3…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.